In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Late breaking trial I - Acute heart failure
Session

Event : Heart Failure 2019

Topic : Acute Heart Failure

  • Session type : Special Session
  • Date : 25 May 2019
  • Time : 08:30 - 10:00

13 presentations in this session

Activity of the Adrenomedullin system to personalize post-discharge treatment in acute heart failure

Event : Heart Failure 2019

  • Session : Late breaking trial I - Acute heart failure
  • Speaker : N Kozhuharov (Basel,CH)

Safety and Efficacy of 24-hour Istaroxime Infusion in Patients Hospitalized for Acute Decompensated Heart Failure

Event : Heart Failure 2019

  • Session : Late breaking trial I - Acute heart failure
  • Speaker : M Metra (Brescia,IT)

Lung Ultrasound Guided Treatment in Ambulatory Patients with Heart Failure: a Randomized Controlled Clinical Trial (LUS-HF study)

Event : Heart Failure 2019

  • Session : Late breaking trial I - Acute heart failure
  • Speaker : M Rivas Lasarte (Barcelona,ES)

Panel Discussion.

Event : Heart Failure 2019

  • Session : Late breaking trial I - Acute heart failure

Discussion -TARGET-1 and TARGET-2.

Event : Heart Failure 2019

  • Session : Late breaking trial I - Acute heart failure

LUS-HF study - Discussion.

Event : Heart Failure 2019

  • Session : Late breaking trial I - Acute heart failure

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are